Anjali Roy

Anjali Roy

Auto-generated profile, based on publicly available information

Anjali Roy

Discipline of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol, 453552, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2020 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
MBMirza Baig
Mirza Baig
ARAnjali Roy
Anjali Roy
SRSajjan Rajpoot
Sajjan Rajpoot
DLDongfang Liu
Dongfang Liu
RSRajkumar Savai
Rajkumar Savai
KWKishore Wary
Kishore Wary

1 November 2016 in International Immunopharmacology
Verified
Journal Article
Closed access
ARAnjali Roy
Anjali Roy
MSMansi Srivastava
Mansi Srivastava
USUzma Saqib
Uzma Saqib
DLDongfang Liu
Dongfang Liu
SFSyed M. Faisal
Syed M. Faisal
MBMirza Baig
Mirza Baig

24 December 2016 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
MSMansi Srivastava
Mansi Srivastava
USUzma Saqib
Uzma Saqib
ANAdnan Naim
Adnan Naim
ARAnjali Roy
Anjali Roy
DLDongfang Liu
Dongfang Liu
MBMirza Baig
Mirza Baig

1 June 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
ARAnjali Roy
Anjali Roy
USUzma Saqib
Uzma Saqib
KWKishore Wary
Kishore Wary
MBMirza Baig
Mirza Baig

20 August 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MBMirza Baig
Mirza Baig
ARAnjali Roy
Anjali Roy
USUzma Saqib
Uzma Saqib
SRSajjan Rajpoot
Sajjan Rajpoot
MSMansi Srivastava
Mansi Srivastava
Rajkumar SavaiRajkumar Savai
Rajkumar Savai
Nuclear factor-kB (NF-kB) is a crucial transcription factor in the signal transduction cascade of the inflammatory signaling. Activation of NF-κB depends on the phosphorylation of IκBα by IκB kinase (IKKβ) followed by subsequent ubiquitination and degradation. This leads to the nuclear translocation of the p50- p65 subunits of NF-κB, and further triggers pro-inflammatory cytokine gene expression. Thus, in the need of a more effective therapy for the treatment of inflammatory diseases, specific inhibition of IKKβ represents a rational alternative strategy to the current therapies. A computer-aided drug identification protocol was followed to identify novel IKKβ inhibitors from a database of over 1500 Food and Drug Administration (FDA) drugs. The best scoring compounds were compared with the already known high-potency IKKβ inhibitors for their ability to bind and inhibit IKKβ by evaluating their docking energy. Finally, Thioridazinehydrochloride (TDZ), a potent antipsychotic drug against Schizophrenia was selected and its efficiency in inhibiting IκBα protein degradation and NF-κB activation was experimentally validated. Our study has demonstrated that TDZ blocks IκBα protein degradation and subsequent NF-κB activation to inhibit inflammation. Thus, it is a potential repurposed drug against inflammation.

1 July 2017 in International Immunopharmacology
Verified
Journal Article
Closed access
MBMirza Baig
Mirza Baig
DLDongfang Liu
Dongfang Liu
KMKannan Muthu
Kannan Muthu
ARAnjali Roy
Anjali Roy
USUzma Saqib
Uzma Saqib
RSRohit Saluja
Rohit Saluja